Nanobodies Market Size, Competitors & Forecast to 2030

Oncology is the fastest growing segment, North America is the largest regional market

The Global Nanobodies Market, valued at USD 578.40 Million in 2024, is projected to experience a CAGR of 18.30% to reach USD 1.58 billion by 2030. Nanobodies, also known as single-domain antibodies, are compact antibody fragments derived from camelids, characterized by their small size, inherent stability, and high antigen affinity. These properties make them valuable for therapeutic, diagnostic, and research applications.

Key Market Drivers

The unique physicochemical properties of nanobodies constitute a primary driver for market expansion, owing to their compact size, inherent stability, and exceptional antigen-binding affinity. These attributes facilitate superior tissue penetration and the targeting of cryptic epitopes, often inaccessible to larger conventional antibodies, thus broadening their therapeutic utility. Nanobodies also exhibit lower immunogenicity, reducing the risk of adverse immune responses. The substantial potential of these characteristics attracts significant investment into companies leveraging nanobody platforms.

Key Market Challenges

The high cost associated with nanobody development and large-scale production represents a major barrier to the expansion of the global nanobodies market. These elevated expenses stem from the complex biotechnological processes, specialised expertise, and advanced infrastructure required throughout the discovery, development, and manufacturing stages. As a result, financial constraints limit the number of nanobody-based therapeutics and diagnostic products that successfully transition from research to commercialisation, thereby slowing overall market growth.

Key Market Trends

Advancements in nanobody production and bioprocessing technologies are significantly influencing the global market by enhancing scalability and reducing manufacturing complexities. The Parenteral Drug Association (PDA), at its 2024 Pharmaceutical Manufacturing & Quality Conference, extensively discussed the adoption of multiple advanced techniques, including flexible manufacturing, continuous manufacturing, and process analytical technology, to optimize bioprocessing efficiency. This focus underscores the industry's drive to streamline production and improve quality control.

Key Market Players Profiled:

Hybrigenics Services
Novo Nordisk A/S
Merck KGaA
Bristol Myers Squibb Company
Boehringer Ingelheim International GmbH
Sanofi S.A
Beroni Group
Shenzhen Kangti Co., Ltd.
GlaxoSmithKline plc
Sensei Biotherapeutics, Inc

Report Scope:

In this report, the Global Nanobodies Market has been segmented into the following categories:

By Type:

Mono-Specific
Multi-Specific

By Application:

Acquired Thrombotic Thrombocytopenic Purpura (TTP)
Respiratory Syncytial Virus Infection
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Oncology
Psoriasis
Chronic Kidney Diseases
Bone Disorders
Others

By End User:

Pharmaceutical & Biotechnology Companies
Research Laboratories
Others

By Region:

North America
Europe
Asia-Pacific
South America
Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nanobodies Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nanobodies Market Outlook

5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Mono-Specific, Multi-Specific)
5.2.2. By Application (Acquired Thrombotic Thrombocytopenic Purpura (TTP), Respiratory Syncytial Virus Infection, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Oncology, Psoriasis, Chronic Kidney Diseases, Bone Disorders, Others)
5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Research Laboratories, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map

6. North America Nanobodies Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Application
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Nanobodies Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Application
6.3.1.2.3. By End User
6.3.2. Canada Nanobodies Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Application
6.3.2.2.3. By End User
6.3.3. Mexico Nanobodies Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Application
6.3.3.2.3. By End User

7. Europe Nanobodies Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Application
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Nanobodies Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. France Nanobodies Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. United Kingdom Nanobodies Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Application
7.3.3.2.3. By End User
7.3.4. Italy Nanobodies Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Application
7.3.4.2.3. By End User
7.3.5. Spain Nanobodies Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Application
7.3.5.2.3. By End User

8. Asia-Pacific Nanobodies Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Application
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Nanobodies Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. India Nanobodies Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. Japan Nanobodies Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. South Korea Nanobodies Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Australia Nanobodies Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Application
8.3.5.2.3. By End User

9. Middle East & Africa Nanobodies Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Application
9.2.3. By End User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Nanobodies Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. UAE Nanobodies Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. South Africa Nanobodies Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Application
9.3.3.2.3. By End User

10. South America Nanobodies Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Application
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Nanobodies Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Colombia Nanobodies Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. Argentina Nanobodies Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Application
10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Nanobodies Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Hybrigenics Services
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Novo Nordisk A/S
15.3. Merck KGaA
15.4. Bristol Myers Squibb Company
15.5. Boehringer Ingelheim International GmbH
15.6. Sanofi S.A
15.7. Beroni Group
15.8. Shenzhen Kangti Co., Ltd.
15.9. GlaxoSmithKline plc
15.10. Sensei Biotherapeutics, Inc

16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

The companies profiled in this Nanobodies market report include:

Hybrigenics Services
Novo Nordisk A/S
Merck KGaA
Bristol Myers Squibb Company
Boehringer Ingelheim International GmbH
Sanofi S.A
Beroni Group
Shenzhen Kangti Co., Ltd.
GlaxoSmithKline plc
Sensei Biotherapeutics, Inc

Table Information

Report Attribute	Details
No. of Pages	183
Published	November 2025
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 578.4 Million
Forecasted Market Value ( USD ) by 2030	$ 1580 Million
Compound Annual Growth Rate	18.3%
Regions Covered	Global
No. of Companies Mentioned	11

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3975EUR$4,500USD£3,483GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4859EUR$5,500USD£4,257GBP

Nanobodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

Key Market Drivers

Key Market Challenges

Key Market Trends

Key Market Players Profiled: